ARO-APOC3 is an investigational therapeutic being evaluated by Arrowhead Pharmaceuticals, Inc. for
the treatment of FCS. A Phase 3 clinical trial, the AROAPOC3-3001 Palisade Study is currently recruiting
adults with a clinical diagnosis of FCS at multiple research centers. To be eligible for the Palisade study
you must:

  • Be 18 years of age or older
  • Have a clinical diagnosis of FCS
  • Have a history of fasting triglyceride levels >880 mg/dL or 10 mmol/L
  • Be willing to maintain a low-fat diet (>20 grams per day) during the 1-year study

Please follow the link to to find out about the Palisade Study including
additional eligibility requirements, the location of the nearest research center, or to learn more about
clinical studies in general.